[144] Medtronic plc SEC Filing

Rhea-AI Filing Summary

A Medtronic (MDT) shareholder filed a Form 144 notice to potentially sell 30,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an approximate aggregate market value of $3,058,452.26. The planned sale date listed is 11/19/2025. The shares come from multiple acquisitions between 2022 and 2025, including employee stock purchase plan buys funded with cash and restricted stock units that vested as compensation. The filing also notes that Medtronic has 1,282,685,882 shares of this class outstanding, giving context for the size of the potential sale relative to the overall share count.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	30000	3058452.26	1282685882	11/19/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/30/2022	ESPP Purchase	Issuer			91	06/30/2022	Cash
Common	09/30/2022	ESPP Purchase	Issuer			123	09/30/2022	Cash
Common	03/31/2023	ESPP Purchase	Issuer			103	03/31/2023	Cash
Common	04/05/2023	Restricted Stock Vesting	Issuer			10620	04/05/2023	Compensation
Common	04/14/2023	Restricted Stock Vesting	Issuer			88	04/14/2023	Compensation
Common	06/30/2023	ESPP Purchase	Issuer			80	06/30/2023	Cash
Common	09/29/2023	ESPP Purchase	Issuer			106	09/29/2023	Cash
Common	12/29/2023	ESPP Purchase	Issuer			16	12/29/2023	Cash
Common	03/28/2024	ESPP Purchase	Issuer			95	03/28/2024	Cash
Common	06/28/2024	ESPP Purchase	Issuer			90	06/28/2024	Cash
Common	07/31/2024	Restricted Stock Vesting	Issuer			3018	07/31/2024	Compensation
Common	08/02/2024	Restricted Stock Vesting	Issuer			4446	08/02/2024	Compensation
Common	09/30/2024	ESPP Purchase	Issuer			107	09/30/2024	Cash
Common	07/31/2025	Restricted Stock Vesting	Issuer			2942	07/31/2025	Compensation
Common	08/01/2025	Restricted Stock Vesting	Issuer			8075	08/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Medtronic (MDT) Form 144 filing disclose?

The Form 144 states that a Medtronic (MDT) shareholder may sell 30,000 shares of common stock, with an aggregate market value of about $3,058,452.26, on the NYSE.

When are the Medtronic (MDT) shares expected to be sold under this Form 144?

The Form 144 lists an approximate sale date of 11/19/2025 for the potential sale of the 30,000 Medtronic common shares.

How were the Medtronic (MDT) shares in this Form 144 acquired?

The shares were acquired between 2022 and 2025 through employee stock purchase plan (ESPP) purchases paid in cash and restricted stock vesting received as compensation from the issuer.

Which broker and exchange are involved in this Medtronic (MDT) Form 144 sale?

The filing identifies Fidelity Brokerage Services LLC as the broker and the NYSE as the exchange where the Medtronic shares may be sold.

How large is the planned Medtronic (MDT) share sale compared with total shares outstanding?

The Form 144 notes that 1,282,685,882 Medtronic common shares are outstanding, providing context for the sale of 30,000 shares.

Does the Medtronic (MDT) Form 144 say anything about undisclosed adverse information?

The signer represents that they do not know any material adverse information about Medtronic’s current or prospective operations that has not been publicly disclosed.